Pfizer completes $31B multi-tranche note offering to fund Seagen acquisition

PFIZER INC

Issued $31B aggregate principal across 8 tranches: 2025-2063 maturities, rates 4.45%-5.34%.
Notes fully and unconditionally guaranteed by Pfizer on a senior unsecured basis.
Special mandatory redemption at 101% if Seagen merger not consummated by Sep 19, 2024 or abandoned.
Net proceeds to finance portion of Seagen deal consideration and related fees; proceeds of 2033/2053 notes for general corporate purposes if redemption triggered.
Issued by wholly-owned Singapore subsidiary Pfizer Investment Enterprises Pte. Ltd.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.